Imdelltra (Tarlatamab-dlle) effects and benefits

The U.S. Food and Drug Administration(FDA) announced that has approvedImdelltra (Tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed during or after platinum-based chemotherapy. Imdelltra has received accelerated approval based on encouraging response rates and duration of response observed in clinical studies. Continued approval for this indication may be contingent upon verification and characterization of clinical benefit in confirmatory trials.

Results from a mid-stage trial (DeLLphi-301 trial) showed that 40% of patients who received 10mg of Imdelltra intravenously every two weeks had tumor shrinkage. The median survival of patients in the study was 14.3 months, compared with the usual survival rate of about 5 months. According to the data, the majority of lung cancer cases are non-small cell lung cancer, while up to 15% are the more aggressive small cell lung cancer targeted by Imdelltra.

Imdelltra binds to DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells. This leads to the formation of cytolytic synapses as cancer cells lyse. DLL3 is a protein expressed on the surface of small cell lung cancer cells in approximately 85-96% of patients with small cell lung cancer, but is rarely expressed in healthy cells, making it an exciting target. Imdelltra is the first and only bispecific T-cell engagement therapy that targets DLL3, activating a patient’s own T cells to attack DLL3-expressing tumor cells.

Imdelltra has anti-tumor activity in mouse models of small cell lung cancer. In clinical trials, the most common side effect of this treatment was cytokine release syndrome, a potentially dangerous condition that occurs when the body's immune system overreacts to an infection or immunotherapy drug.